- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04222257
Short-course Antibiotic Treatment in Gram-positive Cocci Infective Endocarditis (SATIE)
Short-course Antibiotic Regimen Compared to Conventional Antibiotic Treatment for Gram-positive Cocci Infective Endocarditis: Randomized Clinical Trial
Background: it is well known that most serious complications of infective endocarditis (IE) appear in the so-called "critical phase" of the disease, which are the first days after diagnosis. Subsequently, the vast majority of patients who overcome this acute phase has a favourable evolution, and usually stay in the hospital for a long time only to complete antibiotic therapy.
In stable patients with adequate response to antibiotic treatment, without signs of persistent infection or metastatic foci such as spondylodiscitis, it is likely that a shorter antibiotic regimen would be an efficient and safe alternative, as has already been confirmed in patients with IE on tricuspid valves caused by a microorganism considered virulent such as S. aureus. This attractive alternative would improve patients' quality of life, save costs, and decrease the risk of complications related to the adverse effects of prolonged antibiotic treatment.
Objectives: to compare the incidence of the composite endpoint of all-cause mortality, unplanned cardiac surgery, symptomatic embolisms and relapses within 6 months after the inclusion between patients with IE caused by gram-positive cocci receiving a short-course of 2 weeks of antibiotic therapy and those patients receiving conventional antibiotic therapy (4-6 weeks).
Methodology: multicenter, prospective, randomized, controlled open-label, phase IV clinical trial. Sample: patients with IE caused by gram-positive cocci, having received at least 10 days of conventional antibiotic treatment, and at least 7 days after surgery when indicated, without clinical, analytical, microbiological or echocardiographic signs of persistent infection. Estimated sample size: 298 patients. Intervention: Control group: standard antibiotic therapy, according to ESC guidelines recommendations, for 4 to 6 weeks. Experimental group: short-course antibiotic therapy for 2 weeks. The prevalence of previously known risk factors for adverse events will be compared between the two groups to confirm that randomization have worked properly. The incidence of the composite endpoint of all-cause mortality, unplanned cardiac surgery, symptomatic embolisms and relapses within 6 months after the inclusion in the study will be prospectively registered and compared.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Carmen Olmos Blanco, MD
- Phone Number: +0034-913303149
- Email: carmen.olmosblanco@gmail.com
Study Locations
-
-
-
Madrid, Spain, 28040
- Cardiovascular Institute. Hospital Clínico San Carlos
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Definite IE, according to modified ESC 2015 criteria, caused by gram-positive cocci (staphylococci, streptococci and enterococci), including native, prosthetic valve IE and cardiac device-related IE.
- 18 years old or older.
- Patients treated for at least 10 days of appropriate parenteral antibiotic therapy overall (according to guidelines and microbiology sensitivity testing), and at least 7 days of parenteral antibiotic therapy after valve surgery when indicated.
- Absence of fever, microbiological or analytical findings suggesting persistent infection at randomization.
- Absence of locally uncontrolled infection signs (abscess, pseudoaneurysm, fistula, enlarging vegetation) at randomization, confirmed by recent transesophageal echocardiography (performed within 48 h of randomization).
- Women of childbearing potential who will agree to the use of effective contraceptive methods while on antibiotic treatment.
Exclusion Criteria:
- Patients who have received appropriate parenteral antibiotic therapy for infective endocarditis for more than 12 days.
- Patients not suitable to be discharged after 10 days of conventional treatment, due to clinical reasons (sequels of stroke that prevent discharge, progressive renal failure, hepatic failure).
- Patients receiving chemotherapy or immunosuppressive therapy.
- Pregnant or breastfeeding women.
- Need of prolonged antibiotic therapy due to spondylodiscitis or other septic complication.
- Absence of patient's ability or commitment to continue follow-up after being discharged from hospital.
- Inability to give informed consent to participation.
- Cognitive impairment or lack of language skills needed to complete the questionnaires.
- Patients who meet urgent cardiac surgery ESC criteria but are considered inoperable due to high surgical risk.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Short course
Patients allocated to this group will receive a short course of antibiotic therapy for 2 weeks.
|
Patients allocated to this group will receive a short course of antibiotic therapy for 2 weeks.
Patients allocated to continue with standard parenteral treatment will maintain the same antibiotic treatment for 4 to 6 weeks.
|
Active Comparator: Standard course
Those patients allocated to continue with standard parenteral treatment will maintain the same antibiotic treatment for 4 to 6 weeks.
|
Patients allocated to this group will receive a short course of antibiotic therapy for 2 weeks.
Patients allocated to continue with standard parenteral treatment will maintain the same antibiotic treatment for 4 to 6 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Composite endopoint
Time Frame: 6 months
|
To compare the incidence of the composite endpoint that includes all-cause mortality, unplanned cardiac surgery, symptomatic embolisms and relapses within 6 months after the inclusion, between patients with IE caused by gram-positive cocci receiving a short course of 2 weeks of antibiotic therapy and those patients receiving conventional antibiotic therapy for 4-6 weeks.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Perceived quality of life: SF-12
Time Frame: 4 weeks
|
Determination of quality of life (SF-12)
|
4 weeks
|
Functional performance
Time Frame: 4 weeks
|
Determination of functional performance according to the short performance physical battery test (SPPB)
|
4 weeks
|
Clinical complications
Time Frame: 6 months
|
Clinical complications related to hospital stay (nosocomial infections, intravascular catheter-related infections)
|
6 months
|
Total hospital length of stay
Time Frame: 6 months
|
Total hospital length of stay in the next 6 months after the inclusion in the study
|
6 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SATIE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Endocarditis, Bacterial
-
Centre Hospitalier Universitaire de BesanconCHU de Reims; University Hospital, Montpellier; Central Hospital, Nancy, France; Rennes University Hospital and other collaboratorsCompletedInfective Endocarditis
-
University Hospital, EssenCompleted
-
Rigshospitalet, DenmarkOdense University Hospital; Zealand University Hospital; Aarhus University Hospital and other collaboratorsRecruiting
-
Ole HyldegaardRigshospitalet, Denmark; Herlev HospitalUnknownInfectious EndocarditisDenmark
-
University Hospital, Strasbourg, FranceUnknown
-
Emil Loldrup FosbolHvidovre University Hospital; Bispebjerg Hospital; Amager Hospital; Herlev and... and other collaboratorsRecruitingEndocarditis InfectiveDenmark, Netherlands, Sweden
-
Assistance Publique Hopitaux De MarseilleUnknown
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingProsthetic Valve EndocarditisFrance
-
Assiut UniversityRecruitingProsthetic Valve EndocarditisEgypt
-
Montreal Heart InstituteRecruitingInfective Endocarditis | Native Valve EndocarditisCanada
Clinical Trials on Antibiotics
-
Eastern Virginia Medical SchoolNot yet recruitingPreterm Premature Rupture of Membrane
-
Centre Hospitalier Universitaire, AmiensRecruiting
-
Rush University Medical CenterRothman Institute OrthopaedicsCompletedArthroplasty | InfectionUnited States
-
Atlantic Health SystemRecruitingStress Urinary Incontinence | Postoperative Urinary Tract Infection | Urethral BulkingUnited States
-
Southern Illinois UniversityWashington University School of MedicineCompleted
-
Prisma Health-UpstateTerminated
-
Brigham and Women's HospitalDana-Farber Cancer InstituteNot yet recruitingFebrile Neutropenia | Hematologic Malignancy | Antibiotic Stewardship
-
Washington University School of MedicineSt. Louis UniversityTerminatedThe Primary Outcome of This Study Will be the Rate of EndometritisUnited States
-
Children's Hospital of PhiladelphiaCompletedAcute Otitis Media | Acute Sinusitis | Group A Streptococcal PharyngitisUnited States
-
Lady Hardinge Medical CollegeRecruitingAntibiotic Stewardship | Early-Onset Neonatal SepsisIndia